TouchIMMUNOLOGY were delighted to talk with Professor Roy Fleischmann (The University of Texas Southwestern Medical Center and The Metroplex Clinical Research Center, Dallas, TX, US) around the 3 year results from the open-label extension study of upadacitinib or adalimumab in patients with rheumatoid arthritis.
‘Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 3 years From the SELECT-COMPARE Study.’ (POS0087), was presented at the European Congress of Rheumatology 2021, 2-5 June 2021.
- What have we learned from the SELECT-COMPARE study about the efficacy and safety of upadacitinib and adalimumab in patients with rheumatoid arthritis with inadequate response to methotrexate? (0:19)
- Could you tell us a little about the open-label extension study? (2:21)
- What have been the efficacy and safety findings at 3 years, and how do they compare to previous analyses? (4:35)
- Which safety signals are of particular concern, and what are their implications for the future use of TNF inhibitors? (6:25)
- What questions remain unanswered, and what future analyses are planned? (7:57)
Disclosures: Roy Fleischmann discloses being a consultant for AbbVie.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of EULAR 2021 (Virtual).
Share this Video
Related Videos In Rheumatoid Arthritis
Roy Fleischmann, ACR 2021: Efficacy and Safety of Olokizumab plus Methotrexate in a Placebo and Active Controlled Study
Dr Roy Fleischmann (University of Texas Southwestern Medical Center, Dallas, TX, USA) discusses the results from the phase 3, head-to-head, randomized, placebo-controlled clinical trial investigating olokizumab in patients with active rheumatoid arthritis inadequately controlled with methotrexate, with a comparator arm of adalimumab. This information is brought to you by Touch Medical Media and is not […]
Roy Fleischmann, ACR 2021: Safety and Efficacy of Tofacitinib vs TNF Inhibitors in ORAL Surveillance
It was a pleasure to speak with Dr Roy Fleischmann (University of Texas Southwestern Medical Center, Dallas, TX, USA) about ORAL Surveillance (NCT02092467). Mandated by the FDA, due to observed increases in lipids and malignancies in patients with RA treated with tofacitinib, this study was designed to investigate the relative risk of tofacitinib compared to […]
Gilles Boire, ACR 2021: A Mindfulness-Based Program to Improve PROs in patients with Rheumatoid Arthritis
It was a pleasure to discuss with Prof. Gilles Boire (Université de Sherbrooke, Québec, Canada) the recent pilot study in which a Mindfulness-Based Stress Reduction (MBSR) program was offered to patients with controlled rheumatoid arthritis but elevated negative PROs. This information is brought to you by Touch Medical Media and is not sponsored by, nor […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!